GI
ACTU

GAMMA Investing’s Actuate Therapeutics ACTU Stock Holding History

GAMMA Investing’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99 Sell
65
-221
-77% -$512 ﹤0.01% 4114
2026
Q1 		$784 Buy
+286
New +$1.19K ﹤0.01% 3885

Other funds holding ACTU

GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
GRWP
Green Ridge Wealth Planning Montville, New Jersey $238M AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing's ACTU Position: Q2 2026 in Review

GAMMA Investing reduced its Actuate Therapeutics (ACTU) stake by 77% in Q2 2026, selling an estimated $512 and leaving 65 shares worth $99. The position accounts for ﹤0.01% of the portfolio, ranked #4114.

GAMMA Investing first reported a position in ACTU in Q1 2026 and has held it in 2 quarters since. The position peaked at $784 in Q1 2026. 5 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • GAMMA Investing held 65 shares of Actuate Therapeutics worth $99 as of Q2 2026.
  • GAMMA Investing sold 221 Actuate Therapeutics shares in Q2 2026, an estimated $512.
  • Actuate Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #4114 holding.
  • GAMMA Investing first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • GAMMA Investing's Actuate Therapeutics position peaked at $784 in Q1 2026.
  • 5 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.